10-Q: Forian Inc. Reports Second Quarter 2024 Results, Revenue Slightly Down, Operating Loss Increases

Forian Inc. reported a slight decrease in revenue and an increased operating loss for the second quarter of 2024, compared to the same period last year.

Summary

• Forian Inc.'s revenue for the second quarter of 2024 was $4.78 million, a slight decrease from $4.89 million in the same period of 2023.
• The company's operating loss from continuing operations increased to $2.97 million for the quarter, compared to $1.49 million in the second quarter of 2023.
• For the first six months of 2024, revenue was $9.65 million, down from $9.76 million in the first half of 2023.
• The operating loss for the first six months of 2024 was $4.74 million, compared to $3.88 million for the same period in 2023.
• The company's cost of revenues increased significantly, impacting gross profit margins.
• General and administrative expenses also increased, primarily due to professional fees related to a strategic review and bad debt expense.
• Litigation settlements and related expenses were a significant factor, totaling $942,311 for the quarter and $1.15 million for the first six months of 2024.
• The company had two customers representing 16.7% and 11.6% of revenue for the three months ended June 30, 2024.
• The company had two vendors representing 13.5% and 11.2% of purchases and expenses for the three months ended June 30, 2024.

Sentiment

Score: 3

Explanation: The document indicates a negative trend with increased losses and decreased revenue, coupled with ongoing litigation and internal control issues. The company is facing significant challenges in its transition to the healthcare and life sciences sectors.

Positives

• The company redeemed $1 million in principal of convertible notes, resulting in a gain of $137,356.
• The company's cash and marketable securities totaled $48.01 million as of June 30, 2024.

Negatives

• Revenue decreased slightly compared to the same period last year.
• Operating loss increased significantly compared to the same period last year.
• Cost of revenues increased, impacting gross profit margins.
• General and administrative expenses increased.
• Litigation settlements and related expenses were substantial.
• Adjusted EBITDA decreased compared to the same period last year.

Risks

• The company faces risks related to customer concentration, with two customers representing a significant portion of revenue.
• The company is dependent on third-party information vendors, and a change in these relationships could impact operations.
• The company has identified material weaknesses in its internal controls over financial reporting.
• The company is involved in ongoing litigation, which could result in significant expenses.
• The company's future performance is subject to various risks and uncertainties, including those related to the healthcare and life sciences industries.

Future Outlook

The company expects to continue to fund its operations and potential future acquisitions through a combination of cash flow generated from operating activities, available cash and marketable securities, debt financing and/or additional equity issuances.

Management Comments

• Management uses Adjusted EBITDA as an additional measure of the Company's performance for purposes of business decision-making.
• Management believes that the presentation of Adjusted EBITDA is useful to investors in their analysis of the Company's results.

Industry Context

The company operates in the healthcare and life sciences industries, providing data management and analytics solutions. The results reflect the challenges of transitioning from the cannabis industry to these new sectors, including the impact of customer attrition and increased costs.

Comparison to Industry Standards

• It is difficult to make a direct comparison to industry standards without specific benchmarks for companies providing similar data analytics solutions in the healthcare and life sciences sectors.
• However, the increased operating loss and decreased revenue compared to the previous year suggest that Forian is underperforming relative to its own recent history.
• The company's gross profit margin of 62% for the quarter and 64% for the first six months of 2024 is lower than the 74% reported for the same periods in 2023, indicating a potential issue with cost management or pricing strategies.
• The high litigation expenses are also a significant factor that is not typical for companies in this sector, suggesting legacy issues are impacting current performance.
• Companies like IQVIA and Veeva Systems, which are established players in healthcare data and analytics, typically have higher revenue and profitability, but they also have different business models and scale.

Legal Proceedings

• The company settled a lawsuit with former Helix employees, incurring significant litigation expenses.
• The company was involved in a legal proceeding with John Audet, which was settled in March 2024.

Related Party Transactions

• Adam Dublin, the Company's Chief Strategy Officer, received payments from a vendor for runoff commissions on accounts he sold.
• A director of the Company held $6,000,000 of the convertible notes until his death, which notes are now held by his spouse.

Stakeholder Impact

• Shareholders are negatively impacted by the increased operating loss and decreased revenue.
• Employees may be affected by the company's cost-cutting measures and strategic review.
• Customers may be impacted by changes in the company's product offerings and vendor relationships.
• Creditors are exposed to the company's financial challenges and debt obligations.

Next Steps

• The company is evaluating the potential impact of a vendor's decision to no longer include certain data in its licensed products.
• The company is assessing and improving the operating effectiveness of its internal controls over financial reporting.
• The company is continuing to implement newly designed controls and testing their operating effectiveness.

Key Dates

Keywords

financial results, quarterly report, revenue, operating loss, EBITDA, litigation, healthcare analytics, life sciences, financial statements, internal controls